Greg Mayes, Reunion Neuroscience CEO
May 2, 2024 06:30 AM EDT
Financing
Startups

A once-pub­lic psy­che­del­ic biotech reemerges with $103M from MPM and No­vo Hold­ings

Kyle LaHucik

Senior Reporter

MPM BioIm­pact and No­vo Hold­ings are among a group of in­vestors pour­ing $103 mil­lion in­to a psy­che­del­ic biotech that MPM took pri­vate last sum­mer. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

Ma­jor PBM re­forms fea­ture in Con­gress' year-end spend­ing bill

What Trump’s FTC picks mean for bio­phar­ma deal­mak­ing and PBMs

Up­dat­ed: Ver­tex’s non-opi­oid pill dis­ap­points in mid-stage chron­ic pain study

A service from the Financial Times